Biomedical (management/support)
Ended Definitive Contract Awarded Last action
- Contract number
- 00272200009D272002741
- Awardee
-
Bioreliance Corporation UEI H3KAG9A26K77
- Awarding agency
-
NIAID DEA OA Acquisitions
National Institutes of Health, Department of Health and Human Services
- Obligated
- $0
Award facts
- Contract value 0% obligated
-
- $2,198,057.00 Current, with exercised options
- $6,065,128.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325414 Biological Product (except Diagnostic) Manufacturing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Rockville, MD 20850, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$422,150 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $152,150 | |
| Other Administrative Action | $270,000 | |
| Modification | $0 | |
| Supplemental Agreement for work within scope | $0 |
About this award
This federal contract was awarded to Bioreliance Corporation, a foreign-owned, for-profit organization, by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services. The contract, valued at $6,065,128.00, is a definitive contract with a cost-plus-fixed-fee pricing type. Bioreliance, through its Life Sciences Services Division, will provide a range of specialized testing services to support investigational new drug applications, including endotoxin, sterility, and general safety testing. The contract does not have a set-aside designation. Bioreliance has previously secured numerous purchase orders from NIAID and the Centers for Disease Control and Prevention (CDC) for similar services, including isolator sterility testing, Limulus Amebocyte Lysate (LAL) testing for endotoxins, and microbiological examination and bioburden testing. The company has also supported COVID-19 research and vaccine development efforts as a subcontractor.
Quick answers
Who was awarded contract 00272200009D272002741?
00272200009D272002741 was awarded to Bioreliance Corporation by NIAID DEA OA Acquisitions (National Institutes of Health) on March 30, 2005.
How much is contract 00272200009D272002741 worth?
The government has obligated $0 on 00272200009D272002741. Its current value, with exercised options, is $2,198,057. Its potential value, with all options, is $6,065,128.
Was contract 00272200009D272002741 competed?
The extent of competition for 00272200009D272002741 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award